Les maladies neurologiques augmentent-elles le risque ?
Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs.
Maladies neurologiquesSensibilitéRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques voltage-dépendants : Questions médicales les plus fréquentes",
"headline": "Bloqueurs de canaux sodiques voltage-dépendants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bloqueurs de canaux sodiques voltage-dépendants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques",
"url": "https://questionsmedicales.fr/mesh/D026941",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques",
"code": {
"@type": "MedicalCode",
"code": "D026941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"alternateName": "Voltage-Gated Sodium Channel Blockers",
"code": {
"@type": "MedicalCode",
"code": "D061567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "William A Catterall",
"url": "https://questionsmedicales.fr/author/William%20A%20Catterall",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: wcatt@uw.edu."
}
},
{
"@type": "Person",
"name": "Piyasuda Pukkanasut",
"url": "https://questionsmedicales.fr/author/Piyasuda%20Pukkanasut",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Sadanandan E Velu",
"url": "https://questionsmedicales.fr/author/Sadanandan%20E%20Velu",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Tamer M Gamal El-Din",
"url": "https://questionsmedicales.fr/author/Tamer%20M%20Gamal%20El-Din",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA, United States."
}
},
{
"@type": "Person",
"name": "Christopher L-H Huang",
"url": "https://questionsmedicales.fr/author/Christopher%20L-H%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Hopkins Building, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Intrahepatic activated leukocyte cell adhesion molecule induces CD6",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36159854",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.967944"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Occurrence of Activated Leukocyte Cell Adhesion Molecule (ALCAM) and Its Predictive Factors in Patients with Oral Squamous Cell Carcinoma.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36444586",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2022.23.11.3735"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activated Leukocyte Cell Adhesion Molecule (ALCAM), a Potential 'Seed' and 'Soil' Receptor in the Peritoneal Metastasis of Gastrointestinal Cancers.",
"datePublished": "2023-01-03",
"url": "https://questionsmedicales.fr/article/36614319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24010876"
}
},
{
"@type": "ScholarlyArticle",
"name": "Activated leukocyte cell adhesion molecule on human oligodendrocytes mediates CD4 T cell adhesion.",
"datePublished": "2023-08-28",
"url": "https://questionsmedicales.fr/article/37640028",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/brain/awad286"
}
},
{
"@type": "ScholarlyArticle",
"name": "Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39404817",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/rheumatology/keae559"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002317"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bloqueurs de canaux sodiques",
"item": "https://questionsmedicales.fr/mesh/D026941"
},
{
"@type": "ListItem",
"position": 7,
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"item": "https://questionsmedicales.fr/mesh/D061567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bloqueurs de canaux sodiques voltage-dépendants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?\nQuels tests sont utilisés pour évaluer l'effet des bloqueurs ?\nQuels symptômes indiquent une surdose de bloqueurs ?\nComment différencier les types de bloqueurs de canaux ?\nQuels antécédents médicaux sont pertinents pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les symptômes d'une intoxication aiguë ?\nComment se manifestent les effets secondaires des bloqueurs ?\nQuels signes indiquent une réaction allergique ?\nLes bloqueurs affectent-ils la respiration ?\nQuels symptômes neurologiques peuvent apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment prévenir les effets indésirables des bloqueurs ?\nQuelles précautions doivent être prises avant la prescription ?\nLes patients doivent-ils être informés des risques ?\nComment éviter les interactions médicamenteuses ?\nQuelles sont les recommandations pour les patients à risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quel est le traitement d'une surdose de bloqueurs ?\nComment gérer les effets secondaires des bloqueurs ?\nQuels médicaments peuvent interagir avec les bloqueurs ?\nLes bloqueurs sont-ils utilisés en anesthésie ?\nQuelle est l'importance de la surveillance pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quelles complications peuvent survenir avec les bloqueurs ?\nComment les complications sont-elles gérées ?\nLes complications sont-elles fréquentes ?\nQuels facteurs augmentent le risque de complications ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les principaux facteurs de risque ?\nComment l'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'usage de drogues illicites est-il un facteur de risque ?\nLes maladies neurologiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Activated-Leukocyte+Cell+Adhesion+Molecule#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'historique médical, les symptômes cliniques et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des bloqueurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des électrocardiogrammes et des tests de conduction nerveuse peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de bloqueurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, une arythmie cardiaque et une dépression respiratoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment différencier les types de bloqueurs de canaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse des effets cliniques et des mécanismes d'action aide à les différencier."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont pertinents pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques ou neurologiques sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des troubles de la vision et des convulsions."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les effets secondaires des bloqueurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des étourdissements, des maux de tête et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons et un gonflement peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les bloqueurs affectent-ils la respiration ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une dépression respiratoire dans les cas graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques peuvent apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, des troubles de la conscience et des paralysies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des bloqueurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prescription appropriée et une éducation du patient sont essentielles pour prévenir les effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises avant la prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicaux et les allergies du patient est crucial avant la prescription."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients des risques et des signes d'intoxication est essentiel."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen minutieux des médicaments prescrits et des antécédents est nécessaire pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent être suivis de près et éduqués sur les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quel est le traitement d'une surdose de bloqueurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des soins de soutien, l'administration de charbon actif et des antidotes si disponibles."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des bloqueurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique l'ajustement de la dose ou le changement de médicament selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec les bloqueurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antidépresseurs et les anesthésiques peuvent interagir."
}
},
{
"@type": "Question",
"name": "Les bloqueurs sont-ils utilisés en anesthésie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains bloqueurs de canaux sodiques sont utilisés pour induire une anesthésie locale."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance pendant le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les effets indésirables et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les bloqueurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des arythmies, des convulsions et des défaillances respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une intervention rapide et un traitement symptomatique."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout en cas de surdose ou d'interactions."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge avancé, les maladies cardiaques et l'utilisation concomitante d'autres médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance attentive et une éducation adéquate peuvent aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, l'âge et l'utilisation d'autres médicaments sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées ont un risque accru de complications en raison de la polypharmacie et de la fragilité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'usage de drogues illicites est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de certaines drogues peut interagir avec les bloqueurs et augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les maladies neurologiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs."
}
}
]
}
]
}
Autoimmune hepatitis (AIH) is characterized by the expansion and accumulation of pathogenic T cells in liver. Although CD6 and its ligand activated leukocyte cell adhesion molecule (ALCAM) are involve...
Immunohistochemistry was performed to examine hepatic expression of CD6 and ALCAM. The concentration of serum ALCAM was evaluated by ELISA. The phenotypes of liver infiltrating T cells were determined...
Our data showed that patients with AIH exhibited significantly higher expression of CD6 in the liver as compared to primary biliary cholangitis (PBC), chronic hepatitis B (CHB), non-alcoholic liver di...
Our study found that ALCAM-CD6 axis was upregulated in the AIH liver, suggesting a potential target for alleviating AIH....
To determine the occurrence of Activated Leukocyte Cell Adhesion Molecule (ALCAM) and its predictive factors in patients with oral squamous cell carcinoma (OSCC)....
This cross sectional study was concocted on 102 patients with OSCC referred to Imam Khomeini Hospital of Tehran during 1997-2015. The data collection tool a checklist consisted of demographic and path...
the number (%) of men and women were 70 (68.6) and 32 (31.4%), respectively. The mean age (S.D) of participants was 61.7 (15.6) years. Of the total samples, 32 (38.2), 19 (18.6), 36 (35.3) and 8 (7.8%...
The results of our study suggest preliminary evidence for the potential clinical application of ALCAM as a prognostic biomarker for OSCC which may be the basis for future clinical application, however...
Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) is a cell-cell adhesion protein conferring heterotypic and homotypic interactions between cells of the same type and different types. It is abe...
Multiple sclerosis is a chronic neuroinflammatory disorder characterized by demyelination, oligodendrocyte damage/loss and neuroaxonal injury in the context of immune cell infiltration in the central ...
To evaluate urinary activated leucocyte cell adhesion molecule (ALCAM) and CD6 as predictors of lupus nephritis (LN) progression or disease resolution across a 1-year study....
Serum and urine samples from biopsy proven LN subjects (n = 122) were prospectively collected over the course of a year at 3- or 6-month intervals (weeks 0, 12, 26, and 52) across multiple study sites...
Cross-sectional analysis at baseline revealed that urinary ALCAM significantly correlated with urine protein creatinine ratio (UPCR), renal SLEDAI, and the Physician Global Assessment (PGA), and negat...
Urinary ALCAM is reflective of changes in LN and may be predictive of response status....
Intercellular adhesion molecule 1 (ICAM-1) is a transmembrane protein in the immunoglobulin superfamily expressed on the surface of multiple cell populations and upregulated by inflammatory stimuli. I...
The view of prostate cancer (PCa) progression as a result of the interaction of epithelial cancer cells with the host's immune system is supported by the presence of tumor infiltrating lymphocytes (TI...
Functionally relevant CD5 (rs2241002 and rs2229177), CD6 (rs17824933, rs11230563, and rs12360861) and CD166/ALCAM (rs6437585, rs579565, rs1044243, and rs35271455) single nucleotide polymorphisms (SNPs...
Proportional hazards regression showed that the minor CD6 rs12360861...
The results show the impact on PCa aggressiveness and recurrence brought about by gene variants involved in modulation of lymphocyte activation (CD5, CD6) and immune-epithelial cell adhesion (CD166/AL...
Lupus nephritis (LN) is one of the major complications associated with Systemic Lupus Erythematosus (SLE). Activated leukocyte cell adhesion molecule (ALCAM or CD166) is a promising urine biomarker th...
Investigate the urinary ALCAM level in SLE, study its relationship to disease activity, and clarify the association with LN activity and histopathology....
A case-control study was performed on 60 patients with SLE and 20 matched controls. The SLE disease activity index (SLEDAI) and the activity of renal disease (rSLEDAI) were evaluated. Renal biopsy and...
Urinary ALCAM levels were higher significantly in active LN patients than inactive LN patients, active and inactive non-LN SLE, and the control group (p < 0.001). The cut-off value for identifying act...
Urinary ALCAM is a sensitive biomarker evaluating LN in SLE patients. Levels above 270 ng/mg can help distinguish between active and inactive LN. ALCAM levels are correlated positively with SLEDAI and...
The efficiency of inducing human embryonic stem cells into NEUROG3+ pancreatic endocrine cells is a bottleneck in stem cell therapy for diabetes. To understand the cell properties and fate decisions d...
Rupture of intracranial aneurysms (IAs) is the most common cause of subarachnoid hemorrhage (SAH). Currently, there is sufficient evidence to indicate that inflammatory responses contribute to aneurys...